Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,043.29 -6.31 (-0.60%)
Official Closing Price Updated: 7:00 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
News headline image
3 No-Brainer Dividend Stocks to Buy in September ↗
The attraction of these dividend stocks isn't limited to their dividends. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Eli Lilly Loses Appeal Over Medicaid Drug Pricing Fraud Case ↗
A U.S. appeals court upheld a $183.7 million judgment against Eli Lilly in a whistleblower case, finding the company misreported drug prices and shorted Medicaid rebates. 
Via Benzinga
Topics Fraud Whistleblower
Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report ↗
Via Stocktwits
Google DeepMind Chief Eyes Radical AI-Powered Shift In Drug Discovery Speed — Eli Lilly, Novartis Are Already Onboard ↗
Via Stocktwits
Eli Lilly, Novo Nordisk’s Weight-Loss Drugs Deemed Cost-Effective By Pricing Watchdog: BofA Deems Decision A ‘Win’ ↗
Via Stocktwits
News headline image
Here's How Much $100 Invested In Eli Lilly 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
This Under-the-Radar Healthcare Stock Could Soar in 2026 ↗
We should know a lot more by year-end. 
Via The Motley Fool
News headline image
1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street ↗
The positives for this big drugmaker appear to outweigh the negatives. 
Via The Motley Fool
Topics Earnings Government World Trade
News headline image
Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio ↗
The Vanguard Growth ETF provides concentrated exposure to the market's most innovative giants and has a proven history of strong, long-term returns. 
Via MarketBeat
Topics Artificial Intelligence ETFs Economy
News headline image
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback ↗
One of them is already a leader in the market for weight management drugs, and the other could join this field. 
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk’s “Employee Diet” Trims Workforce By 9,000
Via AB Newswire
Topics Economy Workforce
News headline image
Why Eli Lilly's Stock Could Be Gearing Up for a Big Rally ↗
Lilly could launch its GLP-1 pill by this time next year. 
Via The Motley Fool
News headline image
2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades ↗
A decade from now, you could regret ignoring these no-brainer stock picks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Monster Stocks to Hold for the Next 5 Years ↗
These companies each are leaders in today's highest-growth industries. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
News headline image
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets ↗
ICER finds semaglutide and tirzepatide cost-effective for obesity but flags major affordability concerns and limited patient access at current prices. 
Via Benzinga
News headline image
The Smartest Vanguard ETF to Buy With $1,000 Right Now ↗
A fund like the Vanguard Dividend Appreciation ETF can help hedge against a potential market pullback. 
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary' ↗
Novo Nordisk (NYSE: NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant... 
Via Benzinga
News headline image
Defiance Has A New ETF For High-Stakes Pharma Traders ↗
Defiance's LLYZ ETF offers 2X inverse daily exposure to Eli Lilly, giving traders a high-risk, short-term way to bet on stock pullbacks without shorting. 
Via Benzinga
Topics ETFs
News headline image
Eli Lilly Meshes AI With Drug Research, Touts $1B Worth Of Research Data ↗
Eli Lilly's new TuneLab platform gives biotech firms AI-powered drug discovery tools using $1 billion of proprietary research. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
News headline image
Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies ↗
The platform will provide biotech companies access to drug discovery models trained on years of Lilly's research data, the company stated. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
2 Growth Stocks with Explosive Upside and 1 We Brush Off
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Topics Credit Cards
News headline image
1 Reason Every Investor Should Know About Novo Nordisk (NVO) ↗
The company could be on the verge of turning the tide in the battle over weight loss drugs. 
Via The Motley Fool
News headline image
Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients ↗
Jaypirca outperformed chemoimmunotherapy in progression-free survival for chronic lymphocytic leukemia patients in a Phase 3 trial, with positive trends in overall survival. 
Via Benzinga
News headline image
2024 R&D Spending and Intensity Benchmarks
Via PRLog
Topics Supply Chain
News headline image
Ozempic Is The New Botox And Big Pharma Is Printing Billions ↗
Ozempic and Zepbound have helped Novo Nordisk and Eli Lilly achieve a combined market cap topping $900 billion. 
Via Benzinga
News headline image
Looking At Eli Lilly's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (NYSE:LLY) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.